Verastem rides rally to snap up $52M in public offering

Verastem ($VSTM) has capitalized on the soaring value of its shares over the past month and raised $51.9 million from the sale of 3.7 million shares of common stock for $15 per share. Like many biotech companies, The Cambridge, MA-based cancer drug developer, whose shares had slumped after its IPO early last year, has seen its share price spike in recent weeks amid mounting interest in the sector from public investors. Shares of Verastem had climbed more than 78% this year through this morning, according to Google Finance. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.